Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in …
1991 - ashpublications.org
Interferon (IFN) therapy has become widely used for the treatment of chronic myelogenous
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …
[引用][C] Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon α-2b alone or in …
B OPALKA - Blood, 1991 - cir.nii.ac.jp
Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term
treatment with recombinant interferon α-2b alone or in combination with interferon γ | CiNii …
treatment with recombinant interferon α-2b alone or in combination with interferon γ | CiNii …
Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in …
B Opalka, UB Wandl, R Becher, O Kloke… - …, 1991 - pubmed.ncbi.nlm.nih.gov
Interferon (IFN) therapy has become widely used for the treatment of chronic myelogenous
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …
[引用][C] Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon α-2b alone or in …
B OPALKA, UB WANDL, R BECHER, O KLOBE… - Blood, 1991 - pascal-francis.inist.fr
Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term
treatment with recombinant interferon α-2b alone or in combination with interferon γ CNRS …
treatment with recombinant interferon α-2b alone or in combination with interferon γ CNRS …
[HTML][HTML] Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Undergoing Long-term Treatment With Recombinant Interferon a-2b Alone or in …
B Opalka, UB Wandl, R Becher, O Kloke… - Blood, 1991 - Elsevier
Interferon (IFN) therapy has become widely used for the treatment of chronic myelogenous
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …